Remco van Doorn is a dermatologist and professor at Leiden University Medical Center (LUMC), specialising in translational melanoma research. He is also affiliated with the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI). LUMC and NKI are nationwide referral centres for patients with a high risk of melanoma. His research applies insights from genomics, cell biology and immunology to early-stage and hereditary melanoma. Current studies focus on the nevus-to-melanoma transition, cellular senescence as a target for pharmacological treatment of congenital melanocytic nevi, and inactivation of the CDKN2A melanoma susceptibility gene in melanoma development. Another area of research involves analysing skin imaging data for diagnosis and DNA methylation biomarkers for prognosis. Remco is a former member of the European Society for Dermatological Research board.